AUS
NZ
UK
CA
USA
IND
Highlights:
- Quarterly revenue reached $167.8 million, showing growth.
- EPS reported at $0.05, surpassing expectations.
- Market capitalization stands at $2.12 billion.
NeoGenomics (NASDAQ:NEO) operates within the medical research sector, focusing on providing comprehensive genetic testing and related services. As a key player in this industry, the company contributes significantly to advancements in genetic diagnostics and personalized medicine.
Stock Performance Metrics
On Tuesday, NASDAQ NEO opened at $16.53. The stock's 50-day moving average is recorded at $15.80, while the 200-day moving average stands at $15.29. With a market capitalization of $2.12 billion, NeoGenomics is positioned as a mid-cap company within the market. The price-to-earnings (P/E) ratio is -27.10, reflecting current earnings challenges, and the beta value of 1.24 indicates a higher volatility relative to the broader market indices.
Financial Ratios and Stability
NeoGenomics maintains a debt-to-equity ratio of 0.37, suggesting a balanced approach to leveraging debt against shareholder equity. The liquidity of the company is evident through its quick ratio of 1.91 and current ratio of 1.99. These ratios indicate that the company possesses sufficient short-term assets to meet its short-term liabilities, underscoring financial stability.
Quarterly Earnings Report
The latest quarterly earnings report was released on Tuesday, November 5th. NeoGenomics reported earnings per share (EPS) of $0.05 for the quarter, exceeding the consensus estimates of $0.01 by $0.04. This performance marks a significant improvement from the same period last year, where the company reported a negative EPS of ($0.06). The positive EPS indicates a turnaround in the company's earnings performance over the past year.
Profitability Metrics
Despite the revenue growth, NeoGenomics reported a negative return on equity (ROE) of -2.11% and a negative net margin of -12.07%. These profitability metrics indicate that the company faces challenges in converting its revenue into net profits. The negative ROE suggests that the company is not generating sufficient returns on shareholders' equity, while the negative net margin reflects the overall profitability after accounting for all expenses.
Market Position and Competitive Landscape
With a twelve-month low of $12.77 and a twelve-month high of $20.94, NeoGenomics' stock has shown considerable volatility over the past year. The company's position within the medical research sector places it in a competitive landscape alongside other genetic testing and diagnostic firms. The ability to maintain a stable market capitalization of $2.12 billion amidst market fluctuations underscores the company's resilience and adaptability in a dynamic industry.
Future Outlook
Projections for NeoGenomics, Inc. indicate an expected EPS of -0.16 for the current year. This forecast provides insight into the anticipated financial performance and operational challenges the company may face moving forward. The ongoing developments in genetic research and diagnostic services will likely influence the company's strategic initiatives and financial outcomes in the near term.
